New Tumor Cases Confirm Cancer Risks of AAV Gene Therapies

A series of tumor cases reported this year provided convincing evidence that adeno-associated viruses (AAVs) used to deliver gene therapies can cause cancer in certain cases, according to ua.news citing STAT News ua.newsua.newsua.newsOpen source ↗. For two decades, the potential of these small viral vectors to promote oncogenesis remained a subject of scientific debate and was regarded as largely theoretical ua.newsua.newsua.newsOpen source ↗. To date, AAV-based vectors have been administered to thousands of patients worldwide ua.newsua.newsua.newsOpen source ↗.

The documented cases have concluded discussions regarding whether such insertional risks exist in human applications ua.newsua.newsua.newsOpen source ↗. The confirmed oncogenic risk now forces clinicians, researchers, and patients' families to reassess the balance between potential adverse effects and the life-saving efficacy of genetic treatments ua.newsua.newsua.newsOpen source ↗.

According to University of Rochester neurologist Sam McKenzie, this development shifts the balance of considerations for certain patients with spinal muscular atrophy ua.newsua.newsua.newsOpen source ↗. Furthermore, researchers anticipate that analyzing these clinical cases will help establish technical parameters to improve the design and safety profile of future viral delivery platforms ua.newsua.newsua.newsOpen source ↗.